Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim (Kim HJ), Seok O Park (Park SO), Seung-Hyun Ko (Ko SH), Sang Youl Rhee (Rhee SY), Kyu-Yeon Hur (Hur KY), Nan-Hee Kim (Kim NH), Min Kyong Moon (Moon MK), Byung-Wan Lee (Lee BW), Jin Hwa Kim (Kim JH), Kyung Mook Choi (Choi KM),
Diabetes Metab J. 2017;41(6):423-429.   Published online 2017 Dec 19     DOI: https://doi.org/10.4093/dmj.2017.41.6.423
Citations to this article as recorded by Crossref logo
Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
Doo Soo Jeon
Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
Ju-Ming Lu
Advances in Therapy.2019; 36(4): 798.     CrossRef
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
Diabetes Therapy.2019; 10(1): 5.     CrossRef
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim
The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef